Neoadjuvant Nivolumab/Relatlimab Induces High Rates of Pathologic Responses in Patients with Locally Advanced MMR-deficient Colon Cancer By Ogkologos - November 22, 2024 818 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NICHE-3 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab... July 14, 2025 EMA Recommends Granting a Marketing Authorisation for Lurbinectedin April 30, 2026 Benefit in OS with Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant... October 4, 2024 A Single Colonoscopy Reduces CRC Risk, but Not CRC Mortality May 11, 2026 Load more HOT NEWS Doctors Worry Breast Cancer Cases Are Being Missed as Mammogram Rates... FDA Approves Olaparib with Abiraterone and Prednisone (or Prednisolone) for BRCA-mutated... Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than... Treating the Whole Person: How Cancer Centers Are Addressing Social Needs
